Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients

Blood

Volumn 121, Issue 21, 2013, Pages 4366-4376

  Gamazon, Eric R ^a   Lamba, Jatinder K ^b   Pounds, Stanley ^c   Stark, Amy L ^a   Wheeler, Heather E ^a   Cao, Xueyuan ^c   Im, Hae K ^d   Mitra, Amit K ^b   Rubnitz, Jeffrey E ^c   Ribeiro, Raul C ^c   Raimondi, Susana ^c   Campana, Dario ^c   Crews, Kristine R ^c   Wong, Shan S ^a   Welsh, Marleen ^a   Hulur, Imge ^a   Gorsic, Lidija ^a   Hartford, Christine M ^c   Zhang, Wei ^e   Cox, Nancy J ^a   Dolan, M Eileen ^a   more..

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; XEDAR RECEPTOR; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE MYELOID LEUKEMIA; APOPTOSIS; ARTICLE; CANCER PATIENT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SENSITIVITY; EVENT FREE SURVIVAL; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; IC50; LOW DRUG DOSE; LYMPHOBLASTOID CELL LINE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; ACUTE GRANULOCYTIC LEUKEMIA; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; META ANALYSIS; MULTICENTER STUDY; PHENOTYPE; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CYTARABINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; LEUKEMIA, MYELOID, ACUTE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84880435476     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-10-464149     Document Type: Article

References (47)

1. Kumar CC. Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer. 2011;2(2):95-107.
2. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6): 543-552.
3. Imahashi N, Suzuki R, Fukuda T, et al. Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR. Bone Marrow Transplant. 2013;48(1):56-62.
4. Woods WG. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep. Pediatr Blood Cancer. 2006;46(5):565-569.
5. Tallman MS. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology (Am Soc Hematol Educ Program). 2005;143-150.
6. Norsworthy K, Luznik L, Gojo I. New treatment approaches in acute myeloid leukemia: review of recent clinical studies. Rev Recent Clin Trials. 2012;7(3):224-237.
7. Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol. 2009;37(6):649-658.
8. Fernandez-Calotti P, Jordheim LP, Giordano M, Dumontet C, Galmarini CM. Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC). Leuk Lymphoma. 2005;46(3):335-346.
9. Galmarini CM, Thomas X, Calvo F, Rousselot P, El Jafaari A, Cros E, Dumontet C. Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res. 2002;26(7):621-629.
10. Styczynski J. Drug resistance in childhood acute myeloid leukemia. Curr Pharm Biotechnol. 2007; 8(2):59-75.
11. Briasoulis E, Pavlidis N. Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist. 2001;6(2):153-161.
12. Kufe DW, Major PP, Egan EM, Beardsley GP. Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem. 1980;255(19): 8997-900.
13. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia. 2001;15(6):875-890.
14. Kufe DW, Munroe D, Herrick D, Egan E, Spriggs D. Effects of 1-beta-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function. Mol Pharmacol. 1984;26(1):128-134.
15. Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ. Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol. 1985;12(2 suppl 3):20-30.
16. Lamba JK. Pharmacogenomics of cytarabine in childhood leukemia. Pharmacogenomics. 2011; 12(12):1629-1632.
17. Hartford CM, Duan S, Delaney SM, et al. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood. 2009;113(10):2145-2153.
18. Wheeler HE, Gorsic LK, Welsh M, Stark AL, Gamazon ER, Cox NJ, Dolan ME. Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS ONE. 2011;6(7):e21920.
19. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26(17): 2190-2191.
20. Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010;26(18): 2336-2337.
21. Wen Y, Gorsic LK, Wheeler HE, Ziliak DM, Huang RS, Dolan ME. Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics. 2011;21(8): 476-488.
22. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351(6):533-542.
23. Mitra AK, Crews KR, Pounds S, et al. Genetic variants in cytosolic 59-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther. 2011;339(1):9-23.
24. Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009;10(10): 1657-1674.
25. Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci USA. 2010;107(20): 9287-9292.
26. Gamazon ER, Zhang W, Konkashbaev A, et al. SCAN: SNP and copy number annotation. Bioinformatics. 2010;26(2):259-262.
27. Stark AL, Zhang W, Mi S, Duan S, O'Donnell PH, Huang RS, Dolan ME. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 2010;10(6):505-512.
28. Im HK, Gamazon ER, Stark AL, Huang RS, Cox NJ, Dolan ME. Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet. 2012;8(2):e1002525.
29. Smyth GK. Limma: Linear Models for Microarray Data. New York, NY: Springer; 2005
30. Humeniuk R, Menon LG, Mishra PJ, et al. Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity. Leukemia. 2007;21(12):2399-2405.
31. Klco JM, Spencer DH, Lamprecht TL, et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood. 2013; 121(9):1633-1643.
32. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2012;40(Database issue):D930-D934.
33. Kang H, Wilson CS, Harvey RC, et al. Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2012; 119(8):1872-1881.
34. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
35. Zeller T, Wild P, Szymczak S, et al. Genetics and beyond - the transcriptome of human monocytes and disease susceptibility. PLoS ONE. 2010;5(5): e10693.
36. Tanikawa C, Furukawa Y, Yoshida N, Arakawa H, Nakamura Y, Matsuda K. XEDAR as a putative colorectal tumor suppressor that mediates p53-regulated anoikis pathway. Oncogene. 2009; 28(34):3081-3092.
37. Tanikawa C, Ri C, Kumar V, Nakamura Y, Matsuda K. Crosstalk of EDA-A2/XEDAR in the p53 signaling pathway. Mol Cancer Res. 2010; 8(6):855-863.
38. Brach MA, Kharbanda SM, Herrmann F, Kufe DW. Activation of the transcription factor kappa B in human KG-1 myeloid leukemia cells treated with 1-beta-D-arabinofuranosylcytosine. Mol Pharmacol. 1992;41(1):60-63.
39. Kanno S, Hiura T, Shouji A, Osanai Y, Ujibe M, Ishikawa M. Resistance to Ara-C up-regulates the activation of NF-kappaB, telomerase activity and Fas expression in NALM-6 cells. Biol Pharm Bull. 2007;30(11):2069-2074.
40. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98(8):2301-2307.
41. Sigglekow ND, Pangon L, Brummer T, et al. Mutated in colorectal cancer protein modulates the NFkB pathway. Anticancer Res. 2012;32(1): 73-79.
42. Bouwmeester T, Bauch A, Ruffner H, et al. A physical and functional map of the human TNFalpha/NF-kappa B signal transduction pathway. Nat Cell Biol. 2004;6(2):97-105.
43. Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: a novel functional genomics compendium with automated data mining and query reformulation support. Bioinformatics. 1998; 14(8):656-664.
44. Schröder JK, Kirch C, Seeber S, Schütte J. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol. 1998;103(4): 1096-1103.
45. Yang JJ, Cheng C, Yang W, et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA. 2009; 301(4):393-403.
46. Tan XL, Moyer AM, Fridley BL, et al. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res. 2011;17(17): 5801-5811.
47. Huang RS, Johnatty SE, Gamazon ER, et al; Australian Ovarian Cancer Study Group. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res. 2011;17(16): 5490-5500.